KPV: What It Is and Its U.S. Regulatory Status

What is KPV?

KPV is a very short peptide made of three amino acids: lysine, proline and valine. It is not FDA-approved, and the FDA has said it has not identified any human exposure data for drug products containing KPV given by any route.

The KPV sequence forms the tail end, or C-terminus, of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone involved in skin pigmentation and immune signaling.

How it is thought to work

Alpha-MSH has anti-inflammatory effects in addition to its role in pigment. In laboratory studies, the short KPV fragment keeps some of that anti-inflammatory activity. Unlike full-length alpha-MSH, it is not expected to affect skin pigment.

In cell studies, KPV blocks NF-kB, a molecular switch that turns on many inflammatory genes. A 2008 study in the journal Gastroenterology found that gut lining cells take up KPV through a transporter called PepT1, and that KPV given by mouth reduced inflammation in mice with experimentally induced colitis.

What the research measured

Research on KPV has been done almost entirely in cells and animals, mostly in models of gut and skin inflammation. We found no published controlled trials of KPV in people. Results in mice do not show that a compound is safe or effective in humans.

U.S. regulatory status

Current status: Not FDA-approved.

The FDA previously placed KPV in Category 2 of its compounding lists, the group of bulk substances that raise significant safety risks. In April 2026 it was removed from Category 2 because the nomination was withdrawn. That removal does not make it eligible for compounding under section 503A.

At its July 23, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with 1 abstention, to recommend adding KPV to the 503A Bulks List for wound healing and inflammatory conditions. FDA staff had recommended against it, citing inadequate data on impurities, aggregates, bioburden and bacterial endotoxins, and the lack of a USP quality standard. The committee's vote is advisory only. The FDA must still make its own decision and complete formal rulemaking, and as of late September 2026 it had not added the substance to the list. Being on that list would allow compounding with a prescription; it would not make a substance an FDA-approved drug.

KPV is sometimes included in multi-peptide blends sold under brand-style names. Those blends are not approved either. Products sold online as "research chemicals" or labeled "for research purposes only" are not approved medicines, and the FDA has not reviewed their identity, purity or quality.

Documented safety information

In its safety summary, the FDA said it lacks important information about any safety issues raised by KPV, including whether it would cause harm if given to people. Without human studies, its side effects and long-term risks are unknown.

Why Peptide Labs does not sell KPV

Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.

Anyone with questions about KPV, or about gut or skin inflammation, should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.

Related reading

See the full list of compound profiles in the Peptide Guide. KPV was reviewed at the same advisory committee meeting as BPC-157 and TB-500. For the parent hormone's approved relative, see melanotan I (afamelanotide). For the legal background, read whether peptides are legal in the U.S.